NAFDAC approves Johnson and Johnson COVID-19 vaccine

The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the utilisation of the Johnson and Johnson COVID-19 vaccine in Nigeria.

The Director-General of NAFDAC, Prof. Moji Adeyeye, announced this in a statement released on Tuesday endorsed by the representative of the agency, Dr Abubakar Jimoh.

The Director-General of NAFDAC, Prof Mojisola Adeyeye

The statement was named “NAFDAC grants emergency use authorisation for the ‘johnson and johnson’ vaccine’

It read, “NAFDAC is hereby granting conditional emergency use authorisation for Janssen Covid-19 vaccine to prevent COVID-19 in people from 18 years of age.

“After a thorough evaluation, the NAFDAC vaccine committee concluded that the data on the vaccine were robust and met criteria for efficacy, safety, and quality.”

As indicated by her, data have also shown that the advantages of the vaccine exceed its possible danger therefore the necessity for approval.

Adeyeye added that results from a clinical trial involving individuals in the United States, South Africa, and Latin America nations have shown that Janssen Covid-19 vaccine was very beneficial to prevent Covid-19 in individuals from 18 years of age.

In contrast with the AstraZeneca Vaccine which is administered in two dosages, the Janssen vaccine is administered in a single dosage.